Medicines360 Appoints Elizabeth Garner, M.D., M.P.H. to Board of Directors 

HRA Pharma logo

SAN FRANCISCO – May 12, 2022 – Medicines360, the mission-driven nonprofit women’s health pharmaceutical organization, has appointed Elizabeth Garner MD, MPH, as a member of its Board of Directors, effective immediately. With over a decade of pharmaceutical development experience, Dr. Garner brings expansive knowledge in regulatory and clinical affairs, and a deep commitment to increasing […]

Medicines360, Population Services International, and Society for Family Health Announce Launch of Avibela® Hormonal Intrauterine Device in Nigeria

Medicines 360 logo

Improving Access to Modern Contraception for Women in Nigeria  SAN FRANCISCO, WASHINGTON and ABUJA– March 22, 2022– Medicines360, Population Services International (PSI), and Society for Family Health (SFH) announced the launch of Avibela (levonorgestrel-releasing intrauterine system) 52 mg in Nigeria. Nigerian women and girls’ contraceptive options have historically been limited. The introduction of Avibela provides […]

Medicines360 Announces Price Subsidy of its Hormonal IUD Avibela to Expand Access to Contraception

Medicines 360 logo

In August 2021 – Medicines360, the mission-driven nonprofit Women’s Health pharmaceutical organization announced a price subsidy to expand contraceptive access for millions of women in some of the world’s poorest countries. When purchased from its subsidiary, Impact RH360, Avibela will be offered at the price of $9.50 through international procurement groups. “We believe that women […]

Medicines360 and the Population Council Pursue Agreement to Develop Product to Prevent HIV and Unintended Pregnancy for Worldwide Distribution

Medicines 360 logo

SAN FRANCISCO and NEW YORK, N.Y.: Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, and the Population Council, a global nonprofit research organization, have entered into a Memorandum of Understanding to develop a dual prevention pill (DPP) product to prevent both pregnancy and HIV in a single tablet – for global distribution. The organizations intend […]

Medicines360 Statement on New Title X Rule

Medicines 360 logo

As the leading nonprofit pharmaceutical company addressing women’s most pressing reproductive health needs, Medicines360 welcomes the new Department of Health and Human Services (HHS) rule restoring Title X health care providers’ right to give their patients comprehensive, medically accurate health information. “At Medicines360, we know all women deserve access to the full range of contraceptive options and […]

Collaborative Research to Document the Impact of Reimbursement Changes on Access to Long-Acting, Reversible Contraception

Medicines 360 logo

Contraceptive choice, access, and affordability are core determinants of an individuals’ economic and personal health. Access to contraceptives has improved women’s rates of enrollment and graduation from higher education, contributed to significant increases in women’s participation in the workforce, and is connected to increased wages.[i] Federally Qualified Health Centers (FQHCs) are community-based providers that exist to meet patients where […]

Three Things to Know About Our New Vice President of Communications & Marketing

Medicines 360 logo

At Medicines360, our culture is built on a shared passion for advancing women’s health, driven by a team of experts who know the science, and trailblazers who shape new systems and construct solutions for the challenges women face every day. When Stacey Manley previously worked at Medicines360, it marked his first foray into social impact […]

Medicines360, MSI Reproductive Choices and MSK Announce Launch of Avibela® Hormonal Intrauterine Device in Kenya

Medicines 360 logo

Product Expands Access to High-Quality Contraception for Women in Africa SAN FRANCISCO and LONDON and NAIROBI– August 2, 2021 – Medicines360, MSI Reproductive Choices (MSI) and Marie Stopes Kenya (MSK) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Kenya. This is the third launch of Medicines360’s hormonal intrauterine device (IUD) in […]